BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Probert CS, Hearing SD, Schreiber S, Kühbacher T, Ghosh S, Arnott ID, Forbes A. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998-1002. [PMID: 12801957 DOI: 10.1136/gut.52.7.998] [Cited by in Crossref: 233] [Cited by in F6Publishing: 224] [Article Influence: 12.3] [Reference Citation Analysis]
Number Citing Articles
1 Bamba S, Tsujikawa T, Inatomi O, Nakahara T, Koizumi Y, Saitoh Y, Sasaki M, Fujiyama Y, Andoh A. Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis: CSA for ulcerative colitis. Journal of Gastroenterology and Hepatology 2010;25:494-8. [DOI: 10.1111/j.1440-1746.2009.06119.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
2 Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev 2017;9:CD011572. [PMID: 28886205 DOI: 10.1002/14651858.CD011572.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
3 Gisbert JP, González-Lama Y, Maté J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007;25:19-37. [PMID: 17229218 DOI: 10.1111/j.1365-2036.2006.03131.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 79] [Article Influence: 6.2] [Reference Citation Analysis]
4 Khan HM, Mehmood F, Khan N. Optimal management of steroid-dependent ulcerative colitis. Clin Exp Gastroenterol. 2015;8:293-302. [PMID: 26648749 DOI: 10.2147/ceg.s57248] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
5 Kiely CJ, Clark A, Bhattacharyya J, Moran GW, Lee JC, Parkes M. Acetarsol Suppositories: Effective Treatment for Refractory Proctitis in a Cohort of Patients with Inflammatory Bowel Disease. Dig Dis Sci 2018;63:1011-5. [PMID: 29457211 DOI: 10.1007/s10620-017-4890-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Shen B. Impact of preoperative infliximab use on postoperative infectious complications in ulcerative colitis: The price we have to pay?: . Inflammatory Bowel Diseases 2008;14:1019-21. [DOI: 10.1002/ibd.20407] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
7 Ruiz P, San Salvador P, Ortiz de Zárate J, Cabezudo P, Marcé L, Polo F, Blanco S, Orive V. Infliximab como tratamiento en el brote grave de colitis ulcerosa. Gastroenterología y Hepatología 2004;27:430-1. [DOI: 10.1016/s0210-5705(03)70494-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Chaparro M, Burgueño P, Iglesias E, Panés J, Muñoz F, Bastida G, Castro L, Jiménez C, Mendoza JL, Barreiro-de Acosta M, Gómez Senent S, Gomollón F, Calvet X, García-planella E, Gómez M, Hernández V, Hinojosa J, Mañosa M, Pérez Nyssen O, Gisbert JP. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study: Infliximab after ciclosporin failure in ulcerative colitis. Alimentary Pharmacology & Therapeutics 2012;35:275-83. [DOI: 10.1111/j.1365-2036.2011.04934.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 62] [Article Influence: 7.5] [Reference Citation Analysis]
9 Pugliese D, Felice C, Landi R, Papa A, Guidi L, Armuzzi A. Benefit-risk assessment of golimumab in the treatment of refractory ulcerative colitis. Drug Healthc Patient Saf. 2016;8:1-7. [PMID: 26893582 DOI: 10.2147/dhps.s62649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Grinspan A, Kornbluth A. Positioning Therapy for Ulcerative Colitis. Curr Gastroenterol Rep 2015;17:29. [PMID: 26143627 DOI: 10.1007/s11894-015-0454-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
11 Basturk A, Yilmaz A, Keceli M, Artan R. Infliximab treatment in a paediatric patient with ulcerative colitis, who developed acute pancreatitis due to azathioprine during follow-up. Prz Gastroenterol 2017;12:235-7. [PMID: 29123588 DOI: 10.5114/pg.2017.70479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020;115:202-210. [PMID: 31922959 DOI: 10.14309/ajg.0000000000000497] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
13 Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002;122:1592-1608. [PMID: 12016425 DOI: 10.1053/gast.2002.33426] [Cited by in Crossref: 226] [Cited by in F6Publishing: 198] [Article Influence: 11.3] [Reference Citation Analysis]
14 Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Danielsson A, Verbaan H. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811. [PMID: 15940615 DOI: 10.1053/j.gastro.2005.03.003] [Cited by in Crossref: 734] [Cited by in F6Publishing: 651] [Article Influence: 43.2] [Reference Citation Analysis]
15 Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther. 2007;26:779-794. [PMID: 17767462 DOI: 10.1111/j.1365-2036.2007.03334.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
16 Triantafillidis JK, Papalois AE, Parasi A, Anagnostakis E, Burnazos S, Gikas A, Merikas EG, Douzinas E, Karagianni M, Sotiriou H. Favorable response to subcutaneous administration of infliximab in rats with experimental colitis. World J Gastroenterol 2005; 11(43): 6843-6847 [PMID: 16425394 DOI: 10.3748/wjg.v11.i43.6843] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
17 Murphy B, Kavanagh DO, Winter DC. Modern surgery for ulcerative colitis. Updates Surg 2020;72:325-33. [DOI: 10.1007/s13304-020-00719-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Kaur M, Targan SR. Ulcerative colitis: steroid-refractory ulcerative colitis-ciclosporin or infliximab? Nat Rev Gastroenterol Hepatol 2013;10:8-9. [PMID: 23229328 DOI: 10.1038/nrgastro.2012.235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
19 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Samaan MA, Irving PM. The impact of updated NICE guidelines on biologic treatment of ulcerative colitis: reflections on past practices, the changing present and implications for the future. Expert Opin Biol Ther 2016;16:975-7. [PMID: 27186809 DOI: 10.1080/14712598.2016.1189529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Rutgeerts P, van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004;126:1593-610. [DOI: 10.1053/j.gastro.2004.02.070] [Cited by in Crossref: 290] [Cited by in F6Publishing: 256] [Article Influence: 16.1] [Reference Citation Analysis]
22 Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43:482-513. [PMID: 26725569 DOI: 10.1111/apt.13491] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 8.3] [Reference Citation Analysis]
23 Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016;10:607-618. [PMID: 26746169 DOI: 10.1093/ecco-jcc/jjw004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
24 Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis. 2005;11:213-218. [PMID: 15735427 DOI: 10.1097/01.mib.0000160803.44449.a5] [Cited by in Crossref: 73] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
25 Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2014;39:447-58. [PMID: 24444171 DOI: 10.1111/apt.12624] [Cited by in Crossref: 105] [Cited by in F6Publishing: 95] [Article Influence: 13.1] [Reference Citation Analysis]
26 McClements D, Probert C. Managing acute severe ulcerative colitis in the hosptialised setting. Frontline Gastroenterol 2015;6:241-5. [PMID: 28839817 DOI: 10.1136/flgastro-2014-100459] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Pugliese D, Felice C, Papa A, Gasbarrini A, Rapaccini GL, Guidi L, Armuzzi A. Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future. Expert Rev Clin Immunol 2017;13:223-33. [PMID: 27687496 DOI: 10.1080/1744666X.2017.1243468] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
28 Fausel R, Afzali A. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag 2015;11:63-73. [PMID: 25609972 DOI: 10.2147/TCRM.S55506] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
29 Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: a systematic review and meta-analysis. Int J Colorectal Dis 2013;28:287-93. [DOI: 10.1007/s00384-012-1602-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.5] [Reference Citation Analysis]
30 Dean KE, Hikaka J, Huakau JT, Walmsley RS. Infliximab or cyclosporine for acute severe ulcerative colitis: a retrospective analysis. J Gastroenterol Hepatol. 2012;27:487-492. [PMID: 22098019 DOI: 10.1111/j.1440-1746.2011.06958.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
31 Sjöberg M, Walch A, Meshkat M, Gustavsson A, Järnerot G, Vogelsang H, Hertervig E, Novacek G, Friis-Liby I, Blomquist L. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis. 2012;18:212-218. [PMID: 21438096 DOI: 10.1002/ibd.21680] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
32 Miehsler W, Novacek G, Wenzl H, Vogelsang H, Knoflach P, Kaser A, Dejaco C, Petritsch W, Kapitan M, Maier H. A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. J Crohns Colitis. 2010;4:221-256. [PMID: 21122513 DOI: 10.1016/j.crohns.2009.12.001] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
33 Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006;35:821-36. [PMID: 17129815 DOI: 10.1016/j.gtc.2006.09.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
34 Gemayel NC, Rizzello E, Atanasov P, Wirth D, Borsi A. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence. Current Medical Research and Opinion 2019;35:1911-23. [DOI: 10.1080/03007995.2019.1631058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
35 Ford AC, Peyrin-biroulet L. Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials. American Journal of Gastroenterology 2013;108:1268-76. [DOI: 10.1038/ajg.2013.138] [Cited by in Crossref: 226] [Cited by in F6Publishing: 194] [Article Influence: 25.1] [Reference Citation Analysis]
36 Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV, Sandborn WJ, Ullman TA, Moayyedi P. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106 Suppl 1:S2-S25; quiz S26. [PMID: 21472012 DOI: 10.1038/ajg.2011.58] [Cited by in Crossref: 177] [Cited by in F6Publishing: 165] [Article Influence: 16.1] [Reference Citation Analysis]
37 Huang X, Lv B, Jin H, Zhang S. A meta-analysis of the therapeutic effects of tumor necrosis factor-α blockers on ulcerative colitis. Eur J Clin Pharmacol 2011;67:759-66. [DOI: 10.1007/s00228-011-1079-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
38 Buchanan J, Wordsworth S, Ahmad T, Perrin A, Vermeire S, Sans M, Taylor J, Jewell D. Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. J Crohns Colitis 2011;5:301-16. [PMID: 21683300 DOI: 10.1016/j.crohns.2011.02.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
39 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380:1909-1915. [PMID: 23063316 DOI: 10.1016/s0140-6736(12)61084-8] [Cited by in Crossref: 342] [Cited by in F6Publishing: 124] [Article Influence: 34.2] [Reference Citation Analysis]
40 Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-biroulet L, D’haens G, Sandborn WJ, Feagan BG, Jairath V. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology 2018;16:637-647.e13. [DOI: 10.1016/j.cgh.2017.08.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
41 Garud S, Brown A, Cheifetz A, Levitan EB, Kelly CP. Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci 2008;53:875-91. [PMID: 17934839 DOI: 10.1007/s10620-007-9954-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
42 Ljung T, Karlén P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, Sjöqvist U, Löfberg R. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849-853. [PMID: 15138212 DOI: 10.1136/gut.2003.018515] [Cited by in Crossref: 206] [Cited by in F6Publishing: 190] [Article Influence: 11.4] [Reference Citation Analysis]
43 Creed TJ, Probert CS, Norman MN, Moorghen M, Shepherd NA, Hearing SD, Dayan CM; BASBUC INVESTIGATORS. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther. 2006;23:1435-1442. [PMID: 16669958 DOI: 10.1111/j.1365-2036.2006.02904.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 4.4] [Reference Citation Analysis]
44 Ljung T, Thomsen OØ, Vatn M, Karlén P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Löfberg R. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007;42:221-7. [PMID: 17327942 DOI: 10.1080/00365520600979369] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
45 Juillerat P, Christen-Zäch S, Troillet FX, Gallot-Lavallée S, Pannizzon RG, Michetti P. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review. Dermatology. 2007;215:245-251. [PMID: 17823524 DOI: 10.1159/000106584] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
46 D'Haens G. Infliximab for ulcerative colitis: finally some answers. Gastroenterology 2005;128:2161-4. [PMID: 15940648 DOI: 10.1053/j.gastro.2005.04.019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
47 Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The Benefit/Risk Profile of TNF-Blocking Agents: Findings of a Consensus Panel. Seminars in Arthritis and Rheumatism 2005;34:819-36. [DOI: 10.1016/j.semarthrit.2004.11.006] [Cited by in Crossref: 140] [Cited by in F6Publishing: 118] [Article Influence: 8.2] [Reference Citation Analysis]
48 Kim SC, Ferry GD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology. 2004;126:1550-1560. [PMID: 15168366 DOI: 10.1053/j.gastro.2004.03.022] [Cited by in Crossref: 144] [Cited by in F6Publishing: 126] [Article Influence: 8.0] [Reference Citation Analysis]
49 Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55:1255-1262. [PMID: 16484504 DOI: 10.1136/gut.2005.081794] [Cited by in Crossref: 290] [Cited by in F6Publishing: 233] [Article Influence: 18.1] [Reference Citation Analysis]
50 Alzafiri R, Holcroft CA, Malolepszy P, Cohen A, Szilagyi A. Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years. Clin Exp Gastroenterol 2011;4:9-17. [PMID: 21694867 DOI: 10.2147/CEG.S16168] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
51 Ikenoue Y, Tagami T, Murata M. Development and validation of a novel IL-10 deficient cell transfer model for colitis. International Immunopharmacology 2005;5:993-1006. [DOI: 10.1016/j.intimp.2005.01.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
52 Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Stephens M, Evans J, Otley A, Carvalho R, Mack D, Bousvaros A. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010;105:1430-1436. [PMID: 20104217 DOI: 10.1038/ajg.2009.759] [Cited by in Crossref: 88] [Cited by in F6Publishing: 68] [Article Influence: 7.3] [Reference Citation Analysis]
53 Navaneethan U, Shen B. Pros and cons of medical management of ulcerative colitis. Clin Colon Rectal Surg 2010;23:227-38. [PMID: 22131893 DOI: 10.1055/s-0030-1268249] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
54 Sohi S, Cohen RD. Management of refractory ulcerative colitis. Curr Treat Options Gastro 2006;9:234-45. [DOI: 10.1007/s11938-006-0042-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
55 Sjöberg M, Magnuson A, Björk J, Benoni C, Almer S, Friis-Liby I, Hertervig E, Olsson M, Karlén P, Eriksson A. Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Aliment Pharmacol Ther. 2013;38:377-387. [PMID: 23799948 DOI: 10.1111/apt.12387] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
56 Narula N, Marshall JK, Colombel JF, Leontiadis GI, Williams JG, Muqtadir Z, Reinisch W. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016;111:477-491. [PMID: 26856754 DOI: 10.1038/ajg.2016.7] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 15.0] [Reference Citation Analysis]
57 Cuffari C, Present DH, Bayless TM, Lichtenstein GR. Optimizing therapy in patients with pancolitis. Inflamm Bowel Dis 2005;11:937-46. [PMID: 16189424 DOI: 10.1097/01.mib.0000179469.86500.ac] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
58 Kostadinova FI, Baba T, Ishida Y, Kondo T, Popivanova BK, Mukaida N. Crucial involvement of the CX3CR1-CX3CL1 axis in dextran sulfate sodium-mediated acute colitis in mice. J Leukoc Biol. 2010;88:133-143. [PMID: 20335311 DOI: 10.1189/jlb.1109768] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 3.4] [Reference Citation Analysis]
59 Khalif IL, Nanaeva BA, Golovenko AO, Golovenko OV. [Long-term results of medical treatment in patients with a severe attack of ulcerative colitis]. Ter Arkh 2015;87:34-8. [PMID: 25864346 DOI: 10.17116/terarkh201587234-38] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
60 Bitton A, Buie D, Enns R, Feagan BG, Jones JL, Marshall JK, Whittaker S, Griffiths AM, Panaccione R; Canadian Association of Gastroenterology Severe Ulcerative Colitis Consensus Group. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012;107:179-194; author reply 195. [PMID: 22108451 DOI: 10.1038/ajg.2011.386] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 9.6] [Reference Citation Analysis]
61 Järnerot G. Infliximab or Cyclosporine for Severe Ulcerative Colitis. Gastroenterology 2006;130:286. [DOI: 10.1053/j.gastro.2005.11.037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
62 Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13(39): 5238-5244 [PMID: 17876895 DOI: 10.3748/wjg.v13.i39.5238] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
63 Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123-128. [PMID: 17206703 DOI: 10.1002/ibd.20054] [Cited by in Crossref: 126] [Cited by in F6Publishing: 119] [Article Influence: 8.4] [Reference Citation Analysis]
64 Regueiro M, Loftus EV, Steinhart AH, Cohen RD. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006;12:979-994. [PMID: 17012969 DOI: 10.1097/01.mib.0000231495.92013.5e] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 5.1] [Reference Citation Analysis]
65 Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;CD005112. [PMID: 16856078 DOI: 10.1002/14651858.cd005112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 van Assche G, Vermeire S, Rutgeerts P. Emerging Biological Treatments in Inflammatory Bowel Diseases. Dig Dis 2006;24:131-6. [DOI: 10.1159/000090316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
67 Taylor PC, Williams RO, Feldmann M. Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. Curr Opin Biotechnol 2004;15:557-63. [PMID: 15560982 DOI: 10.1016/j.copbio.2004.09.005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
68 Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis. 2009;15:935-950. [PMID: 18985710 DOI: 10.1002/ibd.20797] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 4.0] [Reference Citation Analysis]
69 Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol. 2007;7:13. [PMID: 17389040 DOI: 10.1186/1471-230x-7-13] [Cited by in Crossref: 63] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
70 Caprilli R, Clemente V, Frieri G. Historical evolution of the management of severe ulcerative colitis. Journal of Crohn's and Colitis 2008;2:263-8. [DOI: 10.1016/j.crohns.2008.03.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
71 Laharie D, Rivière P. Letter: should we intensify infliximab in acute severe ulcerative colitis? Aliment Pharmacol Ther 2020;51:186-7. [DOI: 10.1111/apt.15520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
72 Biondi A, Zoccali M, Costa S, Troci A, Contessini-Avesani E, Fichera A. Surgical treatment of ulcerative colitis in the biologic therapy era. World J Gastroenterol 2012; 18(16): 1861-1870 [PMID: 22563165 DOI: 10.3748/wjg.v18.i16.1861] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
73 Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Rev Gastroenterol Hepatol 2007;4:78-91. [DOI: 10.1038/ncpgasthep0695] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
74 Gisbert JP, Chaparro M. Acute severe ulcerative colitis: State of the art treatment. Best Pract Res Clin Gastroenterol 2018;32-33:59-69. [PMID: 30060940 DOI: 10.1016/j.bpg.2018.05.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
75 Whitlow CB. Ulcerative proctitis. Clin Colon Rectal Surg 2004;17:21-7. [PMID: 20011281 DOI: 10.1055/s-2004-823067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
76 Eshuis EJ, Bemelman WA, Stokkers PC. Infliximab for the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;3:219-29. [DOI: 10.1586/egh.09.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
77 Siveke JT, Folwaczny C. Medical approaches and future options in chronic active ulcerative colitis. Int J Colorectal Dis 2004;19:297-307. [PMID: 14727131 DOI: 10.1007/s00384-003-0569-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
78 Danese S, Angelucci E, Malesci A, Caprilli R. Biological agents for ulcerative colitis: hypes and hopes. Med Res Rev. 2008;28:201-218. [PMID: 17464967 DOI: 10.1002/med.20103] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
79 McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol. 2008;42:875-879. [PMID: 18645529 DOI: 10.1097/mcg.0b013e3181354417] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
80 Hoentjen F, Sakuraba A, Hanauer S. Update on the Management of Ulcerative Colitis. Curr Gastroenterol Rep 2011;13:475-85. [DOI: 10.1007/s11894-011-0216-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
81 Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007;132:516-526. [PMID: 17258720 DOI: 10.1053/j.gastro.2006.12.037] [Cited by in Crossref: 102] [Cited by in F6Publishing: 86] [Article Influence: 6.4] [Reference Citation Analysis]
82 Sebastian S, Myers S, Nadir S, Subramanian S. Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis. Dig Dis Sci. 2019;64:1119-1128. [PMID: 30535888 DOI: 10.1007/s10620-018-5407-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
83 Papachristou GI, Plevy S. Novel biologics in inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:251-69, ix. [PMID: 15177537 DOI: 10.1016/j.gtc.2004.02.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
84 Bouhnik Y, Alvès A, Beau P, Carbonnel F, Lévy P. Traitement de la rectocolite ulcéro-hémorragique dans sa forme grave. Gastroentérologie Clinique et Biologique 2004;28:984-91. [DOI: 10.1016/s0399-8320(04)95176-7] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
85 Domènech E, Esteve M, Gomollón F, Hinojosa J, Panés J, Obrador A, Gassull M. Recomendaciones GETECCU-2005 para el uso de infliximab (Remicade®) en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2005;28:126-34. [DOI: 10.1157/13072012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
86 Gomollón F, García-López S, Sicilia B, Gisbert JP, Hinojosa J; en representació del Grupo Espa˜nol de Trabajode Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’sDisease and Ulcerative Colitis (GETECCU). [Therapeutic guidelines on ulcerative colitis: a GRADE methodology based effort of GETECCU]. Gastroenterol Hepatol 2013;36:e1-47. [PMID: 24215088 DOI: 10.1016/j.gastrohep.2012.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
87 Thukral C, Cheifetz A, Peppercorn MA. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date. Drugs 2006;66:2059-65. [PMID: 17112300 DOI: 10.2165/00003495-200666160-00002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
88 Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. Gut Liver 2015;9:18-27. [PMID: 25547087 DOI: 10.5009/gnl14226] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 8.6] [Reference Citation Analysis]
89 Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305-353. [PMID: 29429045 DOI: 10.1007/s00535-018-1439-1] [Cited by in Crossref: 184] [Cited by in F6Publishing: 166] [Article Influence: 46.0] [Reference Citation Analysis]
90 Sobrado CW, Sobrado LF. MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE. Arq Bras Cir Dig 2016;29:201-5. [PMID: 27759787 DOI: 10.1590/0102-6720201600030017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
91 Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, Boulton-Jones R, Williams A, Church N, Satsangi J. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007;26:411-419. [PMID: 17635376 DOI: 10.1111/j.1365-2036.2007.03383.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 6.3] [Reference Citation Analysis]
92 Playford RJ, Ghosh S. Cytokines and growth factor modulators in intestinal inflammation and repair. J Pathol. 2005;205:417-425. [PMID: 15714466 DOI: 10.1002/path.1722] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 1.8] [Reference Citation Analysis]
93 Baudet A, Rahmi G, Bretagne AL, Gloro R, Justum AM, Reimund JM. Severe ulcerative colitis: present medical treatment strategies. Expert Opin Pharmacother. 2008;9:447-457. [PMID: 18220494 DOI: 10.1517/14656566.9.3.447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
94 Petkau JM, Eksteen B. Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab. Biologics 2016;10:33-52. [PMID: 27022240 DOI: 10.2147/BTT.S71679] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
95 Li H, Du Q, Wang RJ, Wang WJ, Li YW, Wu YL. Effect of Kuijieling decoction on DNA binding activity of nuclear factor kappa B in colonic mucosa of rats with ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2008; 16(6): 663-666 [DOI: 10.11569/wcjd.v16.i6.663] [Reference Citation Analysis]
96 Cottone M, Mocciaro F, Modesto I. Infliximab and ulcerative colitis. Expert Opinion on Biological Therapy 2006;6:401-8. [DOI: 10.1517/14712598.6.4.401] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
97 Sharma R, Sharma* CL. TNF-alpha inhibitors: Current indications. Indian Journal of Critical Care Medicine 2007;11:139-48. [DOI: 10.4103/0972-5229.35087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
98 Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol 2015; 21(29): 8776-8786 [PMID: 26269667 DOI: 10.3748/wjg.v21.i29.8776] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
99 Danese S. Adalimumab in ulcerative colitis: Ready for prime time. Digestive and Liver Disease 2013;45:8-13. [DOI: 10.1016/j.dld.2012.05.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
100 Sood A, Midha V, Sharma S, Sood N, Bansal M, Thara A, Khanna P. Infliximab in patients with severe steroid-refractory ulcerative colitis: Indian experience. Indian J Gastroenterol 2014;33:31-4. [PMID: 23999683 DOI: 10.1007/s12664-013-0372-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
101 Bremner AR, Griffiths DM, Beattie RM. Current therapy of ulcerative colitis in children. Expert Opin Pharmacother 2004;5:37-53. [PMID: 14680434 DOI: 10.1517/14656566.5.1.37] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
102 Estevinho MM, Afonso J, Rosa I, Lago P, Trindade E, Correia L, Dias CC, Magro F; GEDII [Portuguese IBD Group]. Placebo Effect on the Health-related Quality of Life of Inflammatory Bowel Disease Patients: A Systematic Review With Meta-analysis. J Crohns Colitis 2018;12:1232-44. [PMID: 30010736 DOI: 10.1093/ecco-jcc/jjy100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
103 Guo C, Wu K, Liang X, Liang Y, Li R. Infliximab clinically treating ulcerative colitis: A systematic review and meta-analysis. Pharmacol Res 2019;148:104455. [PMID: 31562896 DOI: 10.1016/j.phrs.2019.104455] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
104 Hanauer SB. Infliximab as rescue therapy in ulcerative colitis. Curr Gastroenterol Rep 2005;7:465-6. [DOI: 10.1007/s11894-005-0077-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 Pearce CB, Lawrance IC. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J Gastroenterol Hepatol. 2007;22:1671-1677. [PMID: 17845695 DOI: 10.1111/j.1440-1746.2006.04739.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
106 Caprilli R, Viscido A, Latella G. Current management of severe ulcerative colitis. Nat Rev Gastroenterol Hepatol 2007;4:92-101. [DOI: 10.1038/ncpgasthep0687] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
107 Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644-659, quiz 660. [PMID: 21407183 DOI: 10.1038/ajg.2011.73] [Cited by in Crossref: 374] [Cited by in F6Publishing: 353] [Article Influence: 34.0] [Reference Citation Analysis]
108 Herfarth HH, Rogler G, Higgins PD. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? Clin Gastroenterol Hepatol 2015;13:336-8. [PMID: 25285408 DOI: 10.1016/j.cgh.2014.09.045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
109 Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005;25:1181-92. [PMID: 16164393 DOI: 10.1592/phco.2005.25.9.1181] [Cited by in Crossref: 93] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
110 Bultman E, Kuipers EJ, Van Der Woude CJ. Systematic review: steroid withdrawal in anti-TNF-treated patients with inflammatory bowel disease: Systematic review: steroid withdrawal during anti-TNF treatment. Alimentary Pharmacology & Therapeutics 2010;32:313-23. [DOI: 10.1111/j.1365-2036.2010.04373.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
111 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
112 Wang F, Lin X, Zhao Q, Li J. Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis. Eur J Clin Pharmacol 2015;71:911-9. [PMID: 26022220 DOI: 10.1007/s00228-015-1877-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
113 Jairath V, Chan K, Lasch K, Keeping S, Agboton C, Blake A, Patel H. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:711-22. [PMID: 33599181 DOI: 10.1080/17474124.2021.1880319] [Reference Citation Analysis]
114 Van Assche G, Vermeire S, Rutgeerts P. Medical treatment of inflammatory bowel diseases. Curr Opin Gastroenterol. 2005;21:443-447. [PMID: 15930985 DOI: 10.1097/01.mog.0000166752.94169.ca] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
115 Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules. World J Gastroenterol 2006; 12(29): 4628-4635 [PMID: 16937430 DOI: 10.3748/wjg.v12.i29.4628] [Cited by in CrossRef: 74] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]
116 Hindryckx P, Baert F, Hart A, Magro F, Armuzzi A, Peyrin-biroulet L; the Clinical Trial Committee Clincom of the European Crohn’s and Colitis Organisation (ECCO). Clinical Trials in Ulcerative Colitis: A Historical Perspective. ECCOJC 2015;9:580-8. [DOI: 10.1093/ecco-jcc/jjv074] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
117 Moss AC, Peppercorn MA. Steroid-refractory severe ulcerative colitis: what are the available treatment options? Drugs. 2008;68:1157-1167. [PMID: 18547130 DOI: 10.2165/00003495-200868090-00001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
118 Chaparro M. [Advances in the management of ulcerative colitis presented at Digestive Disease Week 2011]. Gastroenterol Hepatol 2011;34 Suppl 2:52-9. [PMID: 22330157 DOI: 10.1016/S0210-5705(11)70021-8] [Reference Citation Analysis]
119 Veres G, Baldassano RN, Mamula P. Infliximab Therapy in Children and Adolescents with Inflammatory Bowel Disease: . Drugs 2007;67:1703-23. [DOI: 10.2165/00003495-200767120-00005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
120 Arora Z, Shen B. Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) 2015;3:103-9. [PMID: 25344680 DOI: 10.1093/gastro/gou070] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
121 Yarlas A, Maher S, Bayliss M, Lovley A, Cappelleri JC, Bushmakin AG, DiBonaventura MD. The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis. J Patient Cent Res Rev 2020;7:189-205. [PMID: 32377552 DOI: 10.17294/2330-0698.1722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 LeBlanc K, Mosli MH, Parker CE, MacDonald JK. The impact of biological interventions for ulcerative colitis on health-related quality of life. Cochrane Database Syst Rev. 2015;CD008655. [PMID: 26393522 DOI: 10.1002/14651858.cd008655.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
123 Casellas i Jordà F. [TNF-alpha inhibitors in inflammatory bowel disease]. Med Clin (Barc) 2004;123:627-34. [PMID: 15546523 DOI: 10.1016/s0025-7753(04)74622-9] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
124 Ross AS, Cohen RD. Medical therapy for ulcerative colitis: The state of the art and beyond. Curr Gastroenterol Rep 2004;6:488-95. [DOI: 10.1007/s11894-004-0071-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
125 Teixeira FV, Vilela EG, Damião AOMC, Vieira A, Albuquerque IC, Parente JML, Chebli JMF, Ambrogini Junior O, Hossne RS, Miszputen SJ. Ulcerative colitis - treatment with biologicals. Rev Assoc Med Bras (1992) 2019;65:547-53. [PMID: 31066808 DOI: 10.1590/1806-9282.65.4.547] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol. 2010;105:1811-1819. [PMID: 20197757 DOI: 10.1038/ajg.2010.95] [Cited by in Crossref: 110] [Cited by in F6Publishing: 107] [Article Influence: 9.2] [Reference Citation Analysis]
127 Díez M, Sánchez E, García López S, Teresa Arroyo M, Gomollón F. Tratamiento con infliximab en la colitis ulcerosa: experiencia inicial en dos centros de referencia. Gastroenterología y Hepatología 2007;30:449-53. [DOI: 10.1157/13110489] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
128 Malhotra S, Bhasin D, Shafiq N, Pandhi P. Drug treatment of ulcerative colitis: unfractionated heparin, low molecular weight heparins and beyond. Expert Opinion on Pharmacotherapy 2005;5:329-34. [DOI: 10.1517/14656566.5.2.329] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
129 Song Y, Zheng P. Efficacy and safety of tumor necrosis factor-α blockers for ulcerative colitis: A systematic review and meta-analysis of published randomized controlled trials. Journal of Food and Drug Analysis 2015;23:1-10. [DOI: 10.1016/j.jfda.2014.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
130 Vellopoulou K, Stefanou G, Tzanetakos C, Boubouchairopoulou N, Nakou M, Gourzoulidis G, Kourlaba G. Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece. Eur J Gastroenterol Hepatol 2021;33:325-33. [PMID: 32976189 DOI: 10.1097/MEG.0000000000001916] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
131 Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, Haslag S, Roberts CC. Safety of Infliximab Treatment in Pediatric Patients with Inflammatory Bowel Disease: . Journal of Pediatric Gastroenterology and Nutrition 2004;39:265-9. [DOI: 10.1097/00005176-200409000-00008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
132 Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1385-1397. e10. [PMID: 27189910 DOI: 10.1016/j.cgh.2016.04.039] [Cited by in Crossref: 179] [Cited by in F6Publishing: 159] [Article Influence: 29.8] [Reference Citation Analysis]
133 Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004;53:780-2. [PMID: 15138201 DOI: 10.1136/gut.2003.020552] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
134 Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004;126:1582-92. [DOI: 10.1053/j.gastro.2004.02.071] [Cited by in Crossref: 120] [Cited by in F6Publishing: 101] [Article Influence: 6.7] [Reference Citation Analysis]
135 Hyman NH, Cataldo P, Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum. 2005;48:70-73. [PMID: 15690660 DOI: 10.1007/s10350-004-0750-5] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
136 Creed TJ, Probert CS. Review article: steroid resistance in inflammatory bowel disease - mechanisms and therapeutic strategies. Aliment Pharmacol Ther. 2007;25:111-122. [PMID: 17229236 DOI: 10.1111/j.1365-2036.2006.03156.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
137 Hanauer SB. Infliximab or Cyclosporine for Severe Ulcerative Colitis. Gastroenterology 2005;129:1358-9. [DOI: 10.1053/j.gastro.2005.08.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
138 Yamada S, Yoshino T, Matsuura M, Kimura M, Koshikawa Y, Minami N, Toyonaga T, Honzawa Y, Nakase H. Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis. Intest Res 2015;13:250-8. [PMID: 26131000 DOI: 10.5217/ir.2015.13.3.250] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
139 Herrlinger KR, Fellermann K, Stange EF. Tacrolimus--finally! Gut 2006;55:1224-5. [PMID: 16905691 DOI: 10.1136/gut.2006.093302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
140 Ardizzone S, Bianchi Porro G. Biologic Therapy for Inflammatory Bowel Disease: . Drugs 2005;65:2253-86. [DOI: 10.2165/00003495-200565160-00002] [Cited by in Crossref: 178] [Cited by in F6Publishing: 178] [Article Influence: 10.5] [Reference Citation Analysis]
141 Legnani P, Kornbluth A. Newer therapies for inflammatory bowel disease. Curr Treat Options Gastro 2004;7:161-7. [DOI: 10.1007/s11938-004-0037-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
142 Lichtenstein GR, Abreu MT, Cohen R, Tremaine W; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987. [PMID: 16530532 DOI: 10.1053/j.gastro.2006.01.048] [Cited by in Crossref: 328] [Cited by in F6Publishing: 303] [Article Influence: 20.5] [Reference Citation Analysis]
143 Masson S, Nylander D, Mansfield JC. How important is onset of action in ulcerative colitis therapy? Drugs. 2005;65:2069-2083. [PMID: 16225364 DOI: 10.2165/00003495-200565150-00001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
144 Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 2008; 14(16): 2544-2549 [PMID: 18442203 DOI: 10.3748/wjg.14.2544] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
145 Ochsenkühn T, Sackmann M, Göke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. European Journal of Gastroenterology & Hepatology 2004;16:1167-71. [DOI: 10.1097/00042737-200411000-00014] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 4.7] [Reference Citation Analysis]
146 Huber R, Ditfurth AV, Amann F, Güthlin C, Rostock M, Trittler R, Kümmerer K, Merfort I. Tormentil for active ulcerative colitis: an open-label, dose-escalating study. J Clin Gastroenterol. 2007;41:834-838. [PMID: 17881930 DOI: 10.1097/mcg.0b013e31804b2173] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
147 Lv R, Qiao W, Wu Z, Wang Y, Dai S, Liu Q, Zheng X. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis. PLoS One. 2014;9:e86692. [PMID: 24475168 DOI: 10.1371/journal.pone.0086692] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
148 Sandborn WJ. Is there a role for infliximab in the treatment of severe ulcerative colitis?: the American experience. Inflamm Bowel Dis 2008;14 Suppl 2:S232-3. [PMID: 18816658 DOI: 10.1002/ibd.20674] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther 2018;47:1578-96. [PMID: 29696670 DOI: 10.1111/apt.14672] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
150 Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53. [PMID: 15972298 DOI: 10.1136/gut.2005.068809] [Cited by in Crossref: 354] [Cited by in F6Publishing: 318] [Article Influence: 20.8] [Reference Citation Analysis]
151 Sartor RB, Hoentjen F. Proinflammatory Cytokines and Signaling Pathways in Intestinal Innate Immune Cells. Mucosal Immunology. Elsevier; 2005. pp. 681-701. [DOI: 10.1016/b978-012491543-5/50039-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
152 Williet N, Sandborn WJ, Peyrin-Biroulet L. Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014;12:1246-1256.e6. [PMID: 24534550 DOI: 10.1016/j.cgh.2014.02.016] [Cited by in Crossref: 153] [Cited by in F6Publishing: 139] [Article Influence: 19.1] [Reference Citation Analysis]
153 Baert F, Vermeire S, Noman M, Van Assche G, D’ Haens G, Rutgeerts P. MANAGEMENT OF ULCERATIVE COLITIS AND CROHN’S DISEASE. Acta Clinica Belgica 2014;59:304-14. [DOI: 10.1179/acb.2004.045] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
154 Thorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis. 2014;8:571-581. [PMID: 24491514 DOI: 10.1016/j.crohns.2014.01.010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
155 Narula N, Fine M, Colombel J, Marshall JK, Reinisch W. Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis. Inflammatory Bowel Diseases 2015;21:1683-94. [DOI: 10.1097/mib.0000000000000350] [Cited by in Crossref: 43] [Cited by in F6Publishing: 14] [Article Influence: 6.1] [Reference Citation Analysis]
156 Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc 2009;7:20. [PMID: 20003364 DOI: 10.1186/1478-7547-7-20] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
157 Braun F, Behrend M. Basic immunosuppressive drugs outside solid organ transplantation. Expert Opin Investig Drugs 2006;15:267-91. [PMID: 16503764 DOI: 10.1517/13543784.15.3.267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
158 Travis S, Stange E, Lémann M, Øresland T, Bemelman W, Chowers Y, Colombel J, D'haens G, Ghosh S, Marteau P, Kruis W, Mortensen N, Penninckx F, Gassull M. European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis 2008;2:24-62. [DOI: 10.1016/j.crohns.2007.11.002] [Cited by in Crossref: 378] [Cited by in F6Publishing: 325] [Article Influence: 27.0] [Reference Citation Analysis]
159 Paschos P, Katsoula A, Salanti G, Giouleme O, Athanasiadou E, Tsapas A. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment Pharmacol Ther. 2018;48:1174-1185. [PMID: 30378141 DOI: 10.1111/apt.15005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
160 Costa J, Magro F, Caldeira D, Alarcão J, Sousa R, Vaz-Carneiro A. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013;19:2098-110. [PMID: 23860567 DOI: 10.1097/MIB.0b013e31829936c2] [Cited by in Crossref: 75] [Cited by in F6Publishing: 27] [Article Influence: 9.4] [Reference Citation Analysis]
161 Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;CD005112. [PMID: 16856078 DOI: 10.1002/14651858.cd005112.pub2] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
162 Lawrance IC. Early investigational TNF receptor antagonists for the treatment of ulcerative colitis. Expert Opin Investig Drugs 2015;24:761-8. [PMID: 25719407 DOI: 10.1517/13543784.2015.1020371] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
163 Kawalec P, Pilc A. An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Arch Med Sci 2016;12:1097-109. [PMID: 27695502 DOI: 10.5114/aoms.2016.58682] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
164 Weber A, Fein F, Koch S, Dupont-gossart A, Mantion G, Heyd B, Carbonnel F. Treatment of ulcerative colitis refractory to steroid therapy by oral microemulsion cyclosporine (neoral): . Inflammatory Bowel Diseases 2006;12:1131-5. [DOI: 10.1097/01.mib.0000235096.78736.8e] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
165 Ross H, Steele SR, Varma M, Dykes S, Cima R, Buie WD, Rafferty J. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. 2014;57:5-22. [PMID: 24316941 DOI: 10.1097/dcr.0000000000000030] [Cited by in Crossref: 107] [Cited by in F6Publishing: 27] [Article Influence: 13.4] [Reference Citation Analysis]
166 Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets 2007;11:1369-84. [PMID: 18028004 DOI: 10.1517/14728222.11.11.1369] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
167 Shen EH, Das KM. Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 2004;38:741-5. [PMID: 15365397 DOI: 10.1097/01.mcg.0000140188.88275.65] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
168 Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol 2015;27:804-12. [PMID: 25933126 DOI: 10.1097/MEG.0000000000000378] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
169 Kugathasan S, Dubinsky MC, Keljo D, Moyer MS, Rufo PA, Wyllie R, Zachos M, Hyams J. Severe Colitis in Children: . Journal of Pediatric Gastroenterology and Nutrition 2005;41:375-85. [DOI: 10.1097/01.mpg.0000186272.65559.ce] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
170 Ebrahimi Daryani N, Najmi Varzaneh F, Hedayat M, Taher M, Farhadi E, Mahmoudi M, Nicknam MH, Bashashati M, Rezaei N. Interleukin-23 receptor single nucleotide polymorphisms in ulcerative colitis. A study in Iranian populations. Clinics and Research in Hepatology and Gastroenterology 2014;38:360-5. [DOI: 10.1016/j.clinre.2013.12.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
171 Nakase H, Yoshino T, Matsuura M. Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use. Inflamm Bowel Dis 2014;20:2151-6. [PMID: 25029618 DOI: 10.1097/MIB.0000000000000130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
172 Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol. 2007;47:930-941. [PMID: 17567930 DOI: 10.1177/0091270007301623] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 5.6] [Reference Citation Analysis]
173 Oussalah A, Laclotte C, Chevaux JB, Bensenane M, Babouri A, Serre AA, Boucekkine T, Roblin X, Bigard MA, Peyrin-Biroulet L. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008;28:966-72. [PMID: 18652603 DOI: 10.1111/j.1365-2036.2008.03811.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
174 Sands BE. New therapies for the treatment of inflammatory bowel disease. Surg Clin North Am. 2006;86:1045-1064. [PMID: 16905423 DOI: 10.1016/j.suc.2006.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
175 Russo EA, Harris AW, Campbell S, Lindsay J, Hart A, Arebi N, Milestone A, Tsai HH, Walters J, Carpani M. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther. 2009;29:308-314. [PMID: 19035973 DOI: 10.1111/j.1365-2036.2008.03890.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
176 Creed TJ, Norman MR, Probert CS, Harvey RF, Shaw IS, Smithson J, Anderson J, Moorghen M, Gupta J, Shepherd NA. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther. 2003;18:65-75. [PMID: 12848627 DOI: 10.1046/j.1365-2036.2003.01639.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 77] [Article Influence: 4.7] [Reference Citation Analysis]
177 Kruis W, Dignass A, Steinhagen-Thiessen E, Morgenstern J, Mössner J, Schreiber S, Vecchi M, Malesci A, Reinshagen M, Löfberg R. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol 2005;11:7001-6. [PMID: 16437606 DOI: 10.3748/wjg.v11.i44.7001] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
178 Flamant M, Bourreille A. Biothérapies et MICI: anti-TNF et nouvelles cibles thérapeutiques. La Revue de Médecine Interne 2007;28:852-61. [DOI: 10.1016/j.revmed.2007.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
179 Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010;10:73. [PMID: 20604939 DOI: 10.1186/1471-230x-10-73] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
180 Kawalec P, Mikrut A, Łopuch S. Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis: Biological therapy for ulcerative colitis. J Gastroenterol Hepatol 2014;29:1159-70. [DOI: 10.1111/jgh.12563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
181 da Luz Moreira A, Vogel JD, Baker M, Mor I, Zhang R, Fazio V. Does CT Influence the Decision to Perform Colectomy in Patients with Severe Ulcerative Colitis? J Gastrointest Surg 2009;13:504-7. [DOI: 10.1007/s11605-008-0732-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
182 Bianchi V, Maconi G, Ardizzone S, Colombo E, Ferrara E, Russo A, Tenchini ML, Porro GB. Association of NOD2/CARD15 mutations on Crohn's disease phenotype in an Italian population. Eur J Gastroenterol Hepatol. 2007;19:217-223. [PMID: 17301648 DOI: 10.1097/01.meg.0000250590.84102.12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
183 Katz S. Update in medical therapy of ulcerative colitis: newer concepts and therapies. J Clin Gastroenterol 2005;39:557-69. [PMID: 16000921 DOI: 10.1097/01.mcg.0000170735.43887.3a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
184 Hauso Ø, Martinsen TC, Waldum H. 5-Aminosalicylic acid, a specific drug for ulcerative colitis. Scandinavian Journal of Gastroenterology 2015;50:933-41. [DOI: 10.3109/00365521.2015.1018937] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
185 Fanjiang G, Russell GH, Katz AJ. Short- and Long-term Response to and Weaning from Infliximab Therapy in Pediatric Ulcerative Colitis. Journal of Pediatric Gastroenterology & Nutrition 2007;44:312-7. [DOI: 10.1097/mpg.0b013e31802e98d4] [Cited by in Crossref: 44] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
186 Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis. Aliment Pharmacol Ther Symp Series 2006;2:147-52. [DOI: 10.1111/j.1746-6342.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
187 Tappenden P, Ren S, Archer R, Harvey R, James MM, Basarir H, Stevens J, Lobo A, Hoque S. A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. Pharmacoeconomics 2016;34:1023-38. [PMID: 27125898 DOI: 10.1007/s40273-016-0409-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
188 Iwasa R, Yamada A, Sono K, Furukawa R, Takeuchi K, Suzuki Y. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study. BMC Gastroenterol 2015;15:103. [PMID: 26271624 DOI: 10.1186/s12876-015-0333-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
189 Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008;51:1202-1207; discussion 1202-1210. [PMID: 18536964 DOI: 10.1007/s10350-008-9364-7] [Cited by in Crossref: 204] [Cited by in F6Publishing: 160] [Article Influence: 14.6] [Reference Citation Analysis]
190 Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39:660-671. [PMID: 24506179 DOI: 10.1111/apt.12644] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 13.0] [Reference Citation Analysis]
191 Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev. 2005;CD004277. [PMID: 15674937 DOI: 10.1002/14651858.cd004277.pub2] [Cited by in Crossref: 49] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
192 Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB. A review of infliximab use in ulcerative colitis. Clin Ther. 2008;30:223-230. [PMID: 18343261 DOI: 10.1016/j.clinthera.2008.02.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
193 Panaccione R, Fedorak RN, Aumais G, Bernard EJ, Bernstein CN, Bitton A, Croitoru K, Dieleman LA, Enns R, Feagan BG, Franchimont D, Greenberg GR, Griffiths AM, Marshall JK, Pare P, Patel S, Penner R, Render C, Seidman E, Steinhart AH. Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol 2008;22:261-72. [PMID: 18354755 DOI: 10.1155/2008/493405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
194 Saniabadi AR, Hanai H. Therapeutic apheresis from the early civilizations to the twenty-first century. Gastroenterol Clin Biol 2010;34:645-8. [PMID: 20971590 DOI: 10.1016/j.gcb.2010.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
195 Lawes D, Taylor I. Recent randomised trials in colorectal disease. Colorectal Dis 2005;7:8-17. [PMID: 15606578 DOI: 10.1111/j.1463-1318.2004.00681.x] [Reference Citation Analysis]
196 Zwiers A, Bouma G. Recent advances in the etiology and treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2006;2:245-56. [PMID: 20477075 DOI: 10.1586/1744666X.2.2.245] [Reference Citation Analysis]
197 Bressler B, Law JK, Al Nahdi Sheraisher N, Atkinson K, Byrne MF, Chung HV, Fishman M, Partovi N, Pearson D, Penner R, Enns RA. The use of infliximab for treatment of hospitalized patients with acute severe ulcerative colitis. Can J Gastroenterol 2008;22:937-40. [PMID: 19018340 DOI: 10.1155/2008/749547] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
198 Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther. 2007;25:1055-1060. [PMID: 17439506 DOI: 10.1111/j.1365-2036.2007.03300.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 79] [Article Influence: 5.7] [Reference Citation Analysis]
199 Alexakis C, Pollok RCG. Impact of thiopurines and anti-tumour necrosis factor therapy on hospitalisation and long-term surgical outcomes in ulcerative colitis. World J Gastrointest Surg 2015; 7(12): 360-369 [PMID: 26730281 DOI: 10.4240/wjgs.v7.i12.360] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
200 Beaugerie L, Blain A, Brazier F, Gornet J, Parc Y. Traitement de la rectocolite ulcéro-hémorragique dans sa forme étendue (colite grave exclue). Gastroentérologie Clinique et Biologique 2004;28:974-83. [DOI: 10.1016/s0399-8320(04)95175-5] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
201 Bewtra M, Lichtenstein GR. Infliximab use in Crohn’s disease. Expert Opinion on Biological Therapy 2005;5:589-99. [DOI: 10.1517/14712598.5.4.589] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
202 Akobeng AK. Infliximab for induction and maintenance theraphy for Ulcerative Colitis: . Journal of Pediatric Gastroenterology and Nutrition 2006;42:589-90. [DOI: 10.1097/01.mpg.0000221896.45910.9a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
203 Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366-73. [PMID: 15306602 DOI: 10.1136/gut.2003.025452] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 2.3] [Reference Citation Analysis]
204 Doherty GA, Cheifetz AS. Management of acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;3:395-405. [DOI: 10.1586/egh.09.24] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
205 Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 2006;40:476-81. [PMID: 16825928 DOI: 10.1097/00004836-200607000-00004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
206 Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther. 2006;23:451-463. [PMID: 16441465 DOI: 10.1111/j.1365-2036.2006.02786.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 162] [Article Influence: 10.5] [Reference Citation Analysis]
207 Barreiro-de Acosta M, Lorenzo A, Mera J, Dominguez-Muñoz JE. Mucosal healing and steroid-sparing associated with infliximab for steroid-dependent ulcerative colitis. J Crohns Colitis 2009;3:271-6. [PMID: 21172286 DOI: 10.1016/j.crohns.2009.06.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
208 Dubinsky MC. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis. Postgraduate Medicine 2017;129:538-53. [DOI: 10.1080/00325481.2017.1319730] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
209 Carbonnel F. Prise en charge d’une rectocolite hémorragique sévère ou corticorésistante. Gastroentérologie Clinique et Biologique 2007;31:398-403. [DOI: 10.1016/s0399-8320(07)89399-7] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
210 Barberio B, Black CJ, Savarino EV, Ford AC. Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. J Crohns Colitis 2021;15:733-41. [PMID: 33175102 DOI: 10.1093/ecco-jcc/jjaa226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
211 Böcker U. Infliximab in ulcerative colitis. Scandinavian Journal of Gastroenterology 2009;41:997-1000. [DOI: 10.1080/00365520600857490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
212 Kühbacher T, Schreiber S, Fölsch UR. Ulcerative colitis: conservative management and long-term effects. Langenbecks Arch Surg. 2004;389:350-353. [PMID: 15133672 DOI: 10.1007/s00423-004-0477-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
213 Thuraisingam A, Leiper K. Medical management of ulcerative colitis. Hosp Med. 2003;64:703-707. [PMID: 14702780 DOI: 10.12968/hosp.2003.64.12.2360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
214 Rosenberg LN, Peppercorn MA. Efficacy and safety of drugs for ulcerative colitis. Expert Opinion on Drug Safety 2010;9:573-92. [DOI: 10.1517/14740331003639412] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
215 Gustavsson A, Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Verbaan H. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther. 2010;32:984-989. [PMID: 20937043 DOI: 10.1111/j.1365-2036.2010.04435.x] [Cited by in Crossref: 127] [Cited by in F6Publishing: 113] [Article Influence: 10.6] [Reference Citation Analysis]
216 Li M, Gao X, Hu PJ. Interleukin-23 and its receptor in Crohn's disease. Shijie Huaren Xiaohua Zazhi 2008; 16(4): 392-398 [DOI: 10.11569/wcjd.v16.i4.392] [Reference Citation Analysis]
217 Narula N, Jharap B, Colombel J. Management of Severe Ulcerative Colitis. Curr Treat Options Gastro 2015;13:59-76. [DOI: 10.1007/s11938-014-0036-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
218 Wang X, Zhou F, Zhao J, Zhou R, Huang M, Li J, Wang W, Xu S, Xia B. Elevated risk of opportunistic viral infection in patients with Crohn’s disease during biological therapies: a meta analysis of randomized controlled trials. Eur J Clin Pharmacol 2013;69:1891-9. [DOI: 10.1007/s00228-013-1559-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
219 Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Basarir H, Stevens J, Carroll C, Cantrell A, Lobo A, Hoque S. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. Health Technol Assess 2016;20:1-326. [PMID: 27220829 DOI: 10.3310/hta20390] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
220 Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis: EFFICACY AND ENDOSCOPIC PREDICTION OF CYTAPHERESIS THERAPY IN UC. Alimentary Pharmacology & Therapeutics 2006;24:147-52. [DOI: 10.1111/j.1365-2036.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
221 Shah B, Mayer L. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 2010;6:607-20. [PMID: 20594134 DOI: 10.1586/eci.10.45] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
222 Cury DB, Cury MS, Elias GVH, Mizsputen SJ. Infliximab to treat severe ulcerative colitis. World J Gastroenterol 2009; 15(14): 1771-1773 [PMID: 19360923 DOI: 10.3748/wjg.15.1771] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
223 Bhattarai A, Kowalczyk W, Tran TN. A literature review on large intestinal hyperelastic constitutive modeling. Clin Biomech (Bristol, Avon) 2021;88:105445. [PMID: 34416632 DOI: 10.1016/j.clinbiomech.2021.105445] [Reference Citation Analysis]
224 Puthoor PR, de Zoeten EF. Pediatric Ulcerative Colitis: The Therapeutic Road to Infliximab. Biol Ther. 2013;3:1-14. [PMID: 24392300 DOI: 10.1007/s13554-012-0006-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
225 Milev S, DiBonaventura MD, Quon P, Wern Goh J, Bourret J, Peeples-Lamirande K, Soonasra A, Cappelleri JC, Quirk D. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States. J Med Econ. 2019;22:859-868. [PMID: 31012362 DOI: 10.1080/13696998.2019.1609481] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
226 Solem CA, Loftus EV Jr. Management of refractory inflammatory bowel disease. Gastroenterol Clin North Am 2004;33:319-34, x. [PMID: 15177541 DOI: 10.1016/j.gtc.2004.02.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
227 Cantor MJ, Nickerson P, Bernstein CN. The Role of Cytokine Gene Polymorphisms in Determining Disease Susceptibility and Phenotype in Inflammatory Bowel Disease. Am J Gastroenterol 2005;100:1134-42. [DOI: 10.1111/j.1572-0241.2005.40979.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 3.6] [Reference Citation Analysis]
228 Vermeire S, Rutgeerts P. Novel biological strategies in inflammatory bowel diseases. Inflamm Bowel Dis 2004;10 Suppl 1:S44-51. [PMID: 15168831 DOI: 10.1097/00054725-200402001-00010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
229 Halpin SJ, Hamlin PJ, Greer DP, Warren L, Ford AC. Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience. World J Gastroenterol 2013; 19(7): 1091-1097 [PMID: 23467174 DOI: 10.3748/wjg.v19.i7.1091] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
230 Hanauer SB, Sparrow M. Therapy of ulcerative colitis. Curr Opin Gastroenterol 2004;20:345-50. [PMID: 15703663 DOI: 10.1097/00001574-200407000-00008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]